About the PROTID Project
This comprehensive project addresses a key EDCTP prevention priority area, namely TB and comorbidities.
We will perform the first randomized controlled trial globally to evaluate the efficacy and impact of preventive treatment of latent tuberculosis infection (LTBI) in people living with diabetes.
We will randomize 3000 people with diabetes and LTBI in Tanzania and Uganda to a 12-week course of rifapentine and isoniazid preventive therapy or placebo, with cumulative incidence of TB disease over at least 24-months follow-up as primary endpoint.
1000 people with diabetes but without evidence of LTBI will be followed in parallel to confirm whether their incidence of TB is too low to warrant preventive treatment.
In addition, we plan to evaluate optimal ways to screen people with DM for LTBI and TB; address gaps in prevention and therapeutic management of combined TB and DM; and estimate the population impact and cost-effectiveness of treatment of LTBI in people living with DM